[A new therapeutic alternative in chronic B-lymphocytic leukemia].
Portal
Elisa
E
D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D016903:Drug Monitoring / Q000379:methods / Q000451:nursing; D006801:Humans; D017053:Infection Control / Q000379:methods; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000097:blood / Q000145:classification / Q000175:diagnosis / Q000188:drug therapy*; D009367:Neoplasm Staging / Q000379:methods; D010353:Patient Education as Topic / Q000379:methods; D012720:Severity of Illness Index
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents; D000074323:Alemtuzumab